

Basic Biology Consortia

Discovery of novel therapeutic targets rooted in a strong biological rationale is a key component of accelerating ALS drug and biomarker development. While it is exciting to witness therapeutics for genetic forms of ALS advance to the clinic, 90% of ALS patients remain in need of new therapies. Given the high unmet need, we are soliciting proposals focused on understanding fundamental biology of the disease to help uncover the next wave of therapeutic targets for sporadic ALS.

Ready to start the application process?

[CLICK HERE TO APPLY](#)

Key Dates



LOI due
February 8,
2024



Invitation to
submit
proposals
March 2024



Proposals
due April 30,
2024



Final
decision
announced
June 2024



Funds
released
July 2024

What We're Funding

[DONATE](#)

[About Us](#) ▾ [For Scientists](#) ▾ [ALS Resources](#) ▾ [Take Action](#) ▾

- » Central and peripheral inflammation
- » Ferroptosis and mechanisms regulating cell survival
- » Neural circuits
- » Environmental risk factors

Confidentiality of investigator's data, research, and intellectual property will be strictly honored.

Target ALS does not seek ownership of any intellectual property or financial gains that result on the basis of its funding.

Who Should Apply

DONATE

[About Us](#) ▾ [For Scientists](#) ▾ [ALS Resources](#) ▾ [Take Action](#) ▾

operational. Only collaborative projects will be considered.



- » Collaborative projects for this call comprise groups of 3-5 laboratories working around a common research theme or target.
- » All collaborators must provide a copy of the executed agreement between their institutions on data/IP sharing OR provide a document that confirms each TTO has been made aware of the collaborative project and the need to sign a data/IP sharing agreement as part of the full proposal submission.
- » Investigators based in industry are encouraged to participate, but their involvement is not a requirement.
- » A Principal Investigator can only participate in one LOI submission.
- » Principal Investigators who have two or more active competitive grants from Target ALS are not eligible to apply.

What Our Grants Support

Funding to cover the following project components:

DONATE

[About Us](#) ▾ [For Scientists](#) ▾ [ALS Resources](#) ▾ [Take Action](#) ▾

with leaders from academia, pharma/biotech, venture capital and other non-profits.

Grant Structure:

- » \$130,000 per lab, per year.
- » The total budget for a collaborative project cannot exceed a maximum of \$500,000 per year.
- » The initial grant will be for a two-year period.
- » The consortium will be eligible to compete for a third year of funding based on a
- » competitive review of updated project goals as well as compelling progress at the end of
- » second year of funding.

[Challenge](#)

[Contact](#)

[Our Approach](#)

[Resources For
Scientists](#)

[Donate](#)

[Call For Proposals](#)

[Funded Consortia](#)

[Annual Meeting](#)

[Privacy Policy](#)

[Credits](#)

FOLLOW US



The Target ALS (TALS) website is intended for informational purposes only. Opinions expressed may not be that of TALS or its employees. For more information about our digital policies, [click here](#).